Article contents
A Clinical and Biochemical Study of Monoamine Oxidase Inhibition in Depressed Patients
I. a Clinical Trial of Nialamide
Published online by Cambridge University Press: 08 February 2018
Extract
The discovery that iproniazid benefits certain subjects with depression, linked with the demonstration that it inhibits the enzyme monoamine oxidase (MAO), led to the hypothesis that inhibition of MAO was the essential mechanism by which iproniazid caused relief of symptoms (Pletscher, 1959). Iproniazid, unfortunately, can produce serious toxic effects, particularly on the liver (Pare and Sandler, 1959), and this has limited its clinical application. For this reason a search has been made for MAO inhibitors with an effective anti-depressant action yet without the serious toxic effects of iproniazid. Among the newer compounds for which such claims have been made is N-isonicotinoyl (-N-N-benzylcarboxamidoethyl) hydrazine or Nialamide.
- Type
- Original Articles
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1961
References
- 7
- Cited by
eLetters
No eLetters have been published for this article.